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We are pleased to present the first issue of Emerging Trends in Drugs,
ddiction, and Health. This is the official Journal of the International
ociety for the Study of Emerging Drugs, a new, Gold Open Access
itle. The mutual goal of both the Society and the Journal, is to pro-
ide a platform for the rapid exchange of multidisciplinary knowledge
n novel psychoactive substances (NPSs), addictions, and their health
ffects. 
he emergence of novel psychoactive substances 
In recent years, there has been a dramatic increase in NPSs detected
cross the world. NPSs include poorly regulated products often sold on-
ine as legal and safer alternatives to internationally controlled drugs,
hose effects they tend to mimic ( Corazza et al., 2014 ). The NPS market
emains highly dynamic and is characterised by the emergence of large
umbers of new substances in a growing number of countries. Between
009 and 2018, 119 countries and territories reported the emergence of
92 NPSs to the United Nations Office on Drugs and Crime (UNODC),
hrough the UNODC Early Warning Advisory on NPSs. Similarly, the
uropean Monitoring Centre for Drugs and Drug Addiction (EMCDDA),
hrough the EU Early Warning System (EWS), monitors over 720 NPSs
hat have appeared since 1997. Of these, 90% has been reported in the
ast decade. The increase in NPSs’ number and availability has primarily
een driven by globalization, the internet, and rapid technology changes
 EMCDDA 2019 ). 
Based on their desired subjective and behavioral effects, four NPS
ategories have been proposed, stimulant, hallucinogenic, cannabi-
oid, and depressant, including a range of agents such as cathinones,
sychedelics, dissociatives, synthetic cannabinoid receptor agonists,
pioids and benzodiazepines ( Tracy et al., 2017 ). However, due to their
hemical structure, NPSs may exhibit complex combinations of these
ctions ( Zawilska, 2015 ). 
Synthetic cannabinoids (SCs) and cathinones are among the most
ommonly used NPSs ( Assi et al., 2017 , Fattore, 2016 ), with young men,
ho also use other substances, as typical users ( Graddy et al., 2018 ).
Cs, for example, emerged as drugs of abuse in the late 2000s. Currently,
ore than 150 SCs are known, with new analogs appearing rapidly, mar-
eted as herbal blends, and often perceived as risk-free by inexperienced
sers ( Armenian et al., 2018 , Davidson et al., 2017 , Fattore, 2016 ).
iven SCs’ structural complexity, there are ample chemical modifica-
ion options that explain their market’s scale and speed and make legalttps://doi.org/10.1016/j.etdah.2020.100001 
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Y-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) ontrol and analytical detection extremely difficult ( Armenian et al.,
018 , Potts et al., 2020 ). 
ovel psychoactive substances and health 
Whereas many NPSs have unknown pharmacology, their molecu-
ar structure and user reports can indicate the expected behavioral and
hysiological effects ( Davidson and Schifano, 2016 ). Claimed desired
ffects of cathinones and SCs, for example, are to enhance empathy and
ncrease the ability to socialize ( Assi et al., 2017 ). In addition to minor
r moderate adverse effects, NPSs have been related to serious compli-
ations, including cardiovascular, neurological, and psychopathological
eactions (e.g., agitation, psychosis), as well as to death ( Assi et al.,
017 ; Graddy et al., 2018 ; Liechti, 2015 ). Although NPSs’ risks can par-
ially be predicted using structurally similar classical illicit substances as
 reference ( Dawson and Moffatt, 2012 ), more research is needed given
he lack of data on risk factors and harms associated with long-term use
f NPSs ( Meader et al., 2018 ). 
Major recently emerged problems have led to an increasing range
f risks for people who use psychoactive substances. These include an
ncrease in the number of highly potent NPSs on the market, many
f which are synthetic cannabinoids or synthetic opioids, and health-
elated circumstances, such as, the Covid-19 pandemic, which might
ontribute to increase mental disturbances and addictive behaviours
 Dubey et al., 2020 ; Rajkumar, 2020 ). Of note, special attention is
eeded for vulnerable groups such as patients with severe mental ill-
esses, or children and adolescents, as NPS-related short-and long-term
ffects might be more pronounced with increased underlying health-
elated disturbances ( Bersani and Prevete, 2017 ; Orsolini et al., 2019 ). 
Among adolescents and young adults, polydrug use is a widespread
henomenon ( Lopez-Rodriguez and Viveros, 2019 ), emphasizing the
eed to study the effects of drug-drug interactions ( Zawilska and An-
rzejczak, 2015 ). Further, data raise the possibility that the use of NPSs
s often associated with the use of “traditional ” drugs as well as with
he occurrence of various forms of addictions, including behavioural
ddictions ( EMCDDA 2017 ; EMCDDA 2019 ; Martinotti et al., 2014 ).
egarding patients with severe mental illnesses, a recent review of
tudies and case reports suggested that NPS use is underestimated in
uch at-risk population and that it can facilitate the exacerbation of
reexisting psychotic disturbances ( Bersani and Prevete, 2017 ). NPS-
elated adverse effects can, when mismanaged or misdiagnosed, be life-
hreatening ( Smith and Robert, 2014 ). he Study of Emerging Drugs. This is an open access article under the CC 


















































































































uture research and publication plan 
In this rapidly changing field, developing a multidisciplinary col-
aboration and a global perspective on the issue is the way forward. A
omprehensive study of NPSs and addiction-related phenomena, in fact,
ncompasses distant disciplines such as pharmacology, clinical practice,
oping science, mental health, public health, forensic medicine, experi-
ental psychology, genetics, molecular biology, internal medicine, neu-
oscience, health psychology, health policy, and health economics. In
elation to detection, web monitoring activities, together with wastew-
ter analyses, clinical and biological observations from healthcare cen-
ers, and analyses of fatal cases, will help in the detection of emergent
ubstances and misuse trends in a time-efficient manner ( Corazza et al.,
014 ; Couto et al., 2018 ). While the development of specific analytic
echniques is needed ( Martinotti et al., 2017 ), continued efforts to ana-
ytically define and confirm agents’ presence in emergency department
dmissions or hospitalizations are necessary ( Logan et al., 2017 ). 
To understand these substances’ safety profile, a well-defined system,
ncluding information about the NPSs’ structure and activity, will hope-
ully allow increasingly fast and accurate communication about trends
f misuse, novel challenges, and potential risks ( Potts et al., 2020 ). This
ystem will hopefully provide a practical framework enabling timely
nd reliable information provision for health professionals for whom
his knowledge is essential when managing intoxication ( Rivera et al.,
017 ). 
Although NPSs’ presence is hard to detect with standard screen-
ng tests, the clinical management of NPS-related physical and psy-
hopathological symptoms hopefully will evolve in the future towards
ore specific evidence-based and molecule-focused treatment strategies
 Schifano et al., 2017 ; Schifano et al., 2016 ). A better understanding of
sers’ motives and profiles could tailor preventative strategies and harm
eduction measures ( d’Angelo et al., 2017 ; Martinotti et al., 2017 ). 
The Journal’s overall purpose is to contribute to improving the
nowledge of complex interactions between NPSs, addiction, and
ealth, with a comprehensive biological, psychological, and social per-
pective. By fostering and stimulating the collaboration between parties
cross nations on the topic of NPSs, this Journal intends to speed up the
cience and the knowledge on the topic, while aiming at enhancing the
ellbeing of people who suffer, and at providing the latest information
o health professionals. 
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